Sapient, a leader in multi-omics data generation, has unveiled DynamiQ™ Insights Engine, the next generation of its human biology database designed to accelerate drug discovery and precision medicine development. The platform represents a significant advancement in biomarker discovery capabilities by integrating diverse multi-omic measures with paired real-world data from serial patient samples.
The newly expanded data infrastructure, developed in collaboration with Rancho Biosciences, enables rapid curation and analysis of Sapient's extensive datasets. Each sample in the DynamiQ platform contains thousands of protein, metabolite, lipid, and cytokine measurements alongside matched genomic data and real-world clinical information including electronic health records, laboratory results, and treatment outcomes.
Comprehensive Longitudinal Data Collection
What sets DynamiQ apart is its temporal dimension. The platform has collected and integrated data from more than 56,000 samples across multiple timepoints, creating one of the most deeply phenotyped longitudinal datasets currently available for biomedical research.
"Disease processes aren't static, and that's why DynamiQ is our differentiator," explained Dr. Jonathan Usuka, Chief Executive Officer at Sapient. "We're focused on the deep characterization of dynamic molecular processes which are read out by proteins and metabolites that modulate, or are modulated by, disease and exposures."
The platform's ability to track molecular changes over time provides researchers with unprecedented insights into disease progression and treatment response. By analyzing samples collected from the same patients at different timepoints alongside their clinical data, DynamiQ can reveal how disease subtypes manifest, how lifestyle factors contribute to outcomes, and how drug exposure and adherence impact biological mechanisms.
Enhanced Analytical Capabilities
Data within the DynamiQ platform has been harmonized across conditions, diagnoses, and outcomes, enabling researchers to rapidly create and analyze cohorts for biomarker discovery, validation, and characterization of therapeutic targets.
Dr. Tao Long, Co-Founder and Head of Data Science at Sapient, highlighted the platform's analytical strengths: "With DynamiQ's next-generation functionality and harmonized datasets, we increase the depth and breadth of analyses we can perform for biomarker discovery, target identification, and clinical insight delivery."
The non-targeted nature of Sapient's multi-omics datasets makes them particularly suitable for artificial intelligence and machine learning applications. These advanced analytical approaches can uncover new patient subgroups, novel biomarkers, and potential drug targets that might otherwise remain hidden in complex biological data.
Applications in Precision Medicine
One of the most promising applications of the DynamiQ platform is in precision medicine, where understanding individual patient responses to treatments is crucial for clinical success.
"This becomes extremely powerful to understand how a therapy will actually work in a patient, to better predict response and stratify patients that are most likely to benefit from a given therapy," Dr. Usuka noted.
Sapient will offer guided analyses using the DynamiQ Insights Engine as part of clients' multi-omic studies or as standalone biocomputational projects. These services aim to help pharmaceutical and biotechnology companies elucidate novel biomarkers, identify new drug targets, and develop diagnostic tools that can improve patient outcomes through more personalized treatment approaches.
The launch of DynamiQ represents a significant step forward in the application of multi-omics data to drug discovery and development, potentially reducing the time and cost of bringing new therapies to patients while increasing the likelihood of clinical success through better patient stratification and biomarker-guided development strategies.
